InO-CHILD im NoW geöffnet.
A Prospective, Randomized, Open-Label Phase 2 Study To Evaluate The Superiority Of Inotuzumab Ozogamicin Monotherapy Versus Allr3 For Induction Treatment Of Childhood High Risk First Relapse B-Cell Precursor Acute Lymphoblastic Leukaemia
Weitere Informationen finden Sie auf 2022-000186-40
Titel der Studie:
A Prospective, Randomized, Open-Label Phase 2 Study To Evaluate The Superiority Of Inotuzumab Ozogamicin Monotherapy Versus Allr3 For Induction Treatment Of Childhood High Risk First Relapse B-Cell Precursor Acute Lymphoblastic Leukaemia